AKT1 and prostate carcinoma: Previous studies have demonstrated that EpCAM knockdown results in increased sensitivity to chemotherapy and radiotherapy in prostate cancer cells, which is interpreted by inactivation of PI3K/AKT/mTOR signaling [58].